Severe hyperglycaemia following pazopanib treatment: The role of drug‐drug‐gene interactions in a patient with metastatic renal cell carcinoma—A case report (CROSBI ID 278878)
Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija
Podaci o odgovornosti
Kuruc Poje, Darija ; Božina, Nada ; Šimičević, Livija ; Žabić, Igor
engleski
Severe hyperglycaemia following pazopanib treatment: The role of drug‐drug‐gene interactions in a patient with metastatic renal cell carcinoma—A case report
What is known and objective Pazopanib is a tyrosine kinase inhibitor with hyperglycaemia as a known adverse event, but case reports of severe hyperglycaemia are exceptional. We report a case of severe hyperglycaemia following pazopanib administration in a patient with metastatic renal cell carcinoma. Case summary Severe hyperglycaemia developed in a patient one month following initiation of pazopanib therapy. As drug‐drug‐gene interactions may lead to hyperglycaemia, pharmacogenetic assessment was requested. The obtained findings indicated intermediate function of both OATP1B1 and P‐glycoprotein transporters, which may cause prolonged pazopanib bioavailability and increased toxicity. Pazopanib was discontinued and, following patient recovery, was reintroduced at a lower dose. What is new and Conclusion The pharmacogenetic profiling of the patient on polypharmacy enabled better management of pazopanib therapy.
pazopanib ; case report ; hyperglycaemia ; polypharmacy ; drug-drug-gene interactions ; pharmacogenetics
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
Podaci o izdanju
45 (4)
2020.
628-631
objavljeno
0269-4727
1365-2710
10.1111/jcpt.13160
Povezanost rada
Kliničke medicinske znanosti